Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Atul Pande is Director at Immunovant. OQRO lists 4 transactions filed with the SEC under this name, the latest on Nov 12, 2026, each linked to the official Form 4.
Director
Disclosures on record
4
Companies involved
1
Atul Pande bought shares on the open market in 2021 and 2022, and has not bought since 2022. Sales in 3 of the 6 years since 2021.
Atul Pande reported 2 open-market purchases and 5 sales since 2021; purchases in 2 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $108K1×1 trade |
| 2024 | — | $221K1×1 trade |
| 2023 | — | $491K3×3 trades |
| 2022 | $84K1×1 trade | — |
| 2021 | $40K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
ImmunovantIMVT
4 disclosures · Dec 2024 – Nov 2026 · 2 sold
Nov 11, 2026Sold~$108Kdisclosed Nov 12
DetailsOfficial recordNov 11, 20263,000disclosed Nov 12
DetailsOfficial recordNov 11, 20263,000disclosed Nov 12
DetailsOfficial recordDec 2, 2024Sold~$221Kdisclosed Dec 4
DetailsOfficial recordAs of the latest filing on , Atul Pande reported holding 116,731 shares of Immunovant (IMVT), worth about $3.71M at the last close of $32 (Nov 20, 2026). In the last 12 months, Atul Pande sold $108K in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Immunovant IMVT | 116,731 | 117K direct | $32 | $3.71M | Nov 11, 2026 |
Is this Atul Pande’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Atul Pande reported 2 open-market purchases and 5 sales here, 2021 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Nov 11, 2026, Atul Pande reported holding 116,731 shares of Immunovant (IMVT). At the last close of $32 on Nov 20, 2026, that is about $3.71M. This is the stake disclosed in filings, not a net worth.
No public filing gives Atul Pande's net worth. What SEC Form 4 shows is the stock stake: 116,731 shares of Immunovant (IMVT), about $3.71M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Atul Pande reported 1 open-market sale worth $108K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Atul Pande bought shares on the open market in 2021 and 2022, and has not bought since 2022. Sales in 3 of the 6 years since 2021.
In SEC filings since 2021: the latest open-market purchase is from 2022; the latest open-market sale is from 2026.
Immunovant (IMVT), from 2021 to 2026: 2 purchases and 5 sales.